Gene deletion and mutation are frequently involved in the development of human urothelial carcinoma, such as the deletion in chromosome 9 (Schulz, 2006; Knowles, 2008), point mutations of the fibroblast growth factor receptor-3 (FGFR3) (Iyer and Milowsky, 2013; Pandith et al., 2013), and alterations in tumor suppressor gene TP53 and RB1 (Mitra et al., 2006) and FHIT (Baffa et al., 2000). This evidence concerns the gene FHIT and urothelial carcinoma.